Baird analyst Joel Beatty lowered the firm’s price target on BeyondSpring to $4 from $11 and keeps an Outperform rating on the shares. The analyst said the target reduction comes after BeyondSpring confirmed that the NDA filing for plinabulin to treat chemotherapy-induced neutropenia has been withdrawn in China.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BYSI: